EMEA (Europe, Middle East and Africa) Hemoglobinopathies Drugs Industry 2017 Market Research Report

Published: Nov, 2017 | Pages: 117 | Publisher: QYResearch
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

In this report, the EMEA Hemoglobinopathies Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Hemoglobinopathies Drugs for these regions, from 2012 to 2022 (forecast)

•	Europe: Germany, France, UK, Russia, Italy and Benelux;
•	Middle East: Saudi Arabia, Israel, UAE and Iran;
•	Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Hemoglobinopathies Drugs market competition by top manufacturers/players, with Hemoglobinopathies Drugs sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including

•	Gamida Cell
•	Alnylam Pharmaceuticals
•	Biogen Idec
•	Sangamo BioSciences Inc.
•	Genetix Pharmaceuticals/Bluebird Bio
•	Global Blood Therapeutics Inc.
•	Pfizer Inc.
•	Mast Therapeutics
•	Emmaus Life Sciences, Inc.
•	Prolong Pharmaceuticals
•	Celgene Corporation
•	HemaQuest Pharmaceuticals

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

•	Thalassemia Therapy
•	Sickle Cell Disease(SCD) Therapy
•	Other Therapy

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

•	Alpha Thalassemia
•	Beta thalassemia
•	Sickle Cell Disease
•	Hb Variants Diseases

If you have any special requirements, please let us know and we will offer you the report as you want.

 Table of Contents

EMEA (Europe, Middle East and Africa) Hemoglobinopathies Drugs Market Report 2017

1 Hemoglobinopathies Drugs Overview
    1.1 Product Overview and Scope of Hemoglobinopathies Drugs
    1.2 Classification of Hemoglobinopathies Drugs
        1.2.1 EMEA Hemoglobinopathies Drugs Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Hemoglobinopathies Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Thalassemia Therapy
        1.2.4 Sickle Cell Disease(SCD) Therapy
        1.2.5 Other Therapy
    1.3 EMEA Hemoglobinopathies Drugs Market by Application/End Users
        1.3.1 EMEA Hemoglobinopathies Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Alpha Thalassemia
        1.3.3 Beta thalassemia
        1.3.4 Sickle Cell Disease
        1.3.5 Hb Variants Diseases
    1.4 EMEA Hemoglobinopathies Drugs Market by Region
        1.4.1 EMEA Hemoglobinopathies Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Hemoglobinopathies Drugs (2012-2022)
        1.5.1 EMEA Hemoglobinopathies Drugs Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Hemoglobinopathies Drugs Revenue and Growth Rate (2012-2022)

2 EMEA Hemoglobinopathies Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Hemoglobinopathies Drugs Market Competition by Players/Manufacturers
        2.1.1 EMEA Hemoglobinopathies Drugs Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Hemoglobinopathies Drugs Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Hemoglobinopathies Drugs Sale Price by Players (2012-2017)
    2.2 EMEA Hemoglobinopathies Drugs (Volume and Value) by Type/Product Category
        2.2.1 EMEA Hemoglobinopathies Drugs Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Hemoglobinopathies Drugs Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Hemoglobinopathies Drugs Sale Price by Type (2012-2017)
    2.3 EMEA Hemoglobinopathies Drugs (Volume) by Application
    2.4 EMEA Hemoglobinopathies Drugs (Volume and Value) by Region
        2.4.1 EMEA Hemoglobinopathies Drugs Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Hemoglobinopathies Drugs Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Hemoglobinopathies Drugs Sales Price by Region (2012-2017)

3 Europe Hemoglobinopathies Drugs (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Hemoglobinopathies Drugs Sales and Value (2012-2017)
        3.1.1 Europe Hemoglobinopathies Drugs Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Hemoglobinopathies Drugs Revenue and Growth Rate (2012-2017)
    3.2 Europe Hemoglobinopathies Drugs Sales and Market Share by Type
    3.3 Europe Hemoglobinopathies Drugs Sales and Market Share by Application
    3.4 Europe Hemoglobinopathies Drugs Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Hemoglobinopathies Drugs Sales Volume by Countries (2012-2017)
        3.4.2 Europe Hemoglobinopathies Drugs Revenue by Countries (2012-2017)
        3.4.3 Germany Hemoglobinopathies Drugs Sales and Growth Rate (2012-2017)
        3.4.4 France Hemoglobinopathies Drugs Sales and Growth Rate (2012-2017)
        3.4.5 UK Hemoglobinopathies Drugs Sales and Growth Rate (2012-2017)
        3.4.6 Russia Hemoglobinopathies Drugs Sales and Growth Rate (2012-2017)
        3.4.7 Italy Hemoglobinopathies Drugs Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Hemoglobinopathies Drugs Sales and Growth Rate (2012-2017)

4 Middle East Hemoglobinopathies Drugs (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Hemoglobinopathies Drugs Sales and Value (2012-2017)
        4.1.1 Middle East Hemoglobinopathies Drugs Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Hemoglobinopathies Drugs Revenue and Growth Rate (2012-2017)
    4.2 Middle East Hemoglobinopathies Drugs Sales and Market Share by Type
    4.3 Middle East Hemoglobinopathies Drugs Sales and Market Share by Application
    4.4 Middle East Hemoglobinopathies Drugs Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Hemoglobinopathies Drugs Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Hemoglobinopathies Drugs Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Hemoglobinopathies Drugs Sales and Growth Rate (2012-2017)
        4.4.4 Israel Hemoglobinopathies Drugs Sales and Growth Rate (2012-2017)
        4.4.5 UAE Hemoglobinopathies Drugs Sales and Growth Rate (2012-2017)
        4.4.6 Iran Hemoglobinopathies Drugs Sales and Growth Rate (2012-2017)

5 Africa Hemoglobinopathies Drugs (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Hemoglobinopathies Drugs Sales and Value (2012-2017)
        5.1.1 Africa Hemoglobinopathies Drugs Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Hemoglobinopathies Drugs Revenue and Growth Rate (2012-2017)
    5.2 Africa Hemoglobinopathies Drugs Sales and Market Share by Type
    5.3 Africa Hemoglobinopathies Drugs Sales and Market Share by Application
    5.4 Africa Hemoglobinopathies Drugs Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Hemoglobinopathies Drugs Sales Volume by Countries (2012-2017)
        5.4.2 Africa Hemoglobinopathies Drugs Revenue by Countries (2012-2017)
        5.4.3 South Africa Hemoglobinopathies Drugs Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Hemoglobinopathies Drugs Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Hemoglobinopathies Drugs Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Hemoglobinopathies Drugs Sales and Growth Rate (2012-2017)

6 EMEA Hemoglobinopathies Drugs Manufacturers/Players Profiles and Sales Data
    6.1 Gamida Cell
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Hemoglobinopathies Drugs Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Gamida Cell Hemoglobinopathies Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Alnylam Pharmaceuticals
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Hemoglobinopathies Drugs Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Alnylam Pharmaceuticals Hemoglobinopathies Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Biogen Idec
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Hemoglobinopathies Drugs Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Biogen Idec Hemoglobinopathies Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Sangamo BioSciences Inc.
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Hemoglobinopathies Drugs Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Sangamo BioSciences Inc. Hemoglobinopathies Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Genetix Pharmaceuticals/Bluebird Bio
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Hemoglobinopathies Drugs Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Global Blood Therapeutics Inc.
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Hemoglobinopathies Drugs Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Pfizer Inc.
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Hemoglobinopathies Drugs Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Pfizer Inc. Hemoglobinopathies Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Mast Therapeutics
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Hemoglobinopathies Drugs Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Mast Therapeutics Hemoglobinopathies Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Emmaus Life Sciences, Inc.
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Hemoglobinopathies Drugs Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Prolong Pharmaceuticals
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Hemoglobinopathies Drugs Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Prolong Pharmaceuticals Hemoglobinopathies Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Celgene Corporation
    6.12 HemaQuest Pharmaceuticals

7 Hemoglobinopathies Drugs Manufacturing Cost Analysis
    7.1 Hemoglobinopathies Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Hemoglobinopathies Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Hemoglobinopathies Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Hemoglobinopathies Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Hemoglobinopathies Drugs Market Forecast (2017-2022)
    11.1 EMEA Hemoglobinopathies Drugs Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Hemoglobinopathies Drugs Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Hemoglobinopathies Drugs Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Hemoglobinopathies Drugs Price and Trend Forecast (2017-2022)
    11.2 EMEA Hemoglobinopathies Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Hemoglobinopathies Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Hemoglobinopathies Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Hemoglobinopathies Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Hemoglobinopathies Drugs Sales Forecast by Type (2017-2022)
    11.7 EMEA Hemoglobinopathies Drugs Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer

List of Tables and Figures

    Figure Product Picture of Hemoglobinopathies Drugs
    Figure EMEA Hemoglobinopathies Drugs Sales Volume (K Pcs) by Type (2012-2022)
    Figure EMEA Hemoglobinopathies Drugs Sales Volume Market Share by Type (Product Category) in 2016
    Figure Thalassemia Therapy Product Picture
    Figure Sickle Cell Disease(SCD) Therapy Product Picture
    Figure Other Therapy Product Picture
    Figure EMEA Hemoglobinopathies Drugs Sales Volume (K Pcs) by Application (2012-2022)
    Figure EMEA Sales Market Share of Hemoglobinopathies Drugs by Application in 2016
    Figure Alpha Thalassemia Examples
    Table Key Downstream Customer in Alpha Thalassemia
    Figure Beta thalassemia Examples
    Table Key Downstream Customer in Beta thalassemia
    Figure Sickle Cell Disease Examples
    Table Key Downstream Customer in Sickle Cell Disease
    Figure Hb Variants Diseases Examples
    Table Key Downstream Customer in Hb Variants Diseases
    Figure EMEA Hemoglobinopathies Drugs Market Size (Million USD) by Region (2012-2022)
    Figure Europe Hemoglobinopathies Drugs Revenue (Million USD) and Growth Rate (2012-2022)
    Figure Europe Hemoglobinopathies Drugs Revenue (Million USD) Status and Forecast by Countries
    Figure Middle East Hemoglobinopathies Drugs Revenue (Million USD) and Growth Rate (2012-2022)
    Figure Middle East Hemoglobinopathies Drugs Revenue (Million USD) Status and Forecast by Countries
    Figure Africa Hemoglobinopathies Drugs Revenue (Million USD) and Growth Rate (2012-2022)
    Figure Africa Hemoglobinopathies Drugs Revenue (Million USD) Status and Forecast by Countries
    Figure EMEA Hemoglobinopathies Drugs Sales Volume and Growth Rate (2012-2022)
    Figure EMEA Hemoglobinopathies Drugs Revenue (Million USD) and Growth Rate (2012-2022)
    Figure EMEA Hemoglobinopathies Drugs Market Major Players Product Sales Volume (K Pcs) (2012-2017)
    Table EMEA Hemoglobinopathies Drugs Sales Volume (K Pcs) of Major Players (2012-2017)
    Table EMEA Hemoglobinopathies Drugs Sales Share by Players (2012-2017)
    Figure 2016 Hemoglobinopathies Drugs Sales Share by Players
    Figure 2017 Hemoglobinopathies Drugs Sales Share by Players
    Figure EMEA Hemoglobinopathies Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
    Table EMEA Hemoglobinopathies Drugs Revenue (Million USD) by Players (2012-2017)
    Table EMEA Hemoglobinopathies Drugs Revenue Share by Players (2012-2017)
    Table 2016 EMEA Hemoglobinopathies Drugs Revenue Share by Players
    Table 2017 EMEA Hemoglobinopathies Drugs Revenue Share by Players
    Table EMEA Hemoglobinopathies Drugs Sale Price (USD/Pcs) by Players (2012-2017)
    Table EMEA Hemoglobinopathies Drugs Sales (K Pcs) and Market Share by Type (2012-2017)
    Table EMEA Hemoglobinopathies Drugs Sales Share by Type (2012-2017)
    Figure Sales Market Share of Hemoglobinopathies Drugs by Type (2012-2017)
    Figure EMEA Hemoglobinopathies Drugs Sales Market Share by Type (2012-2017)
    Table EMEA Hemoglobinopathies Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
    Table EMEA Hemoglobinopathies Drugs Revenue Share by Type (2012-2017)
    Figure Revenue Market Share of Hemoglobinopathies Drugs by Type in 2016
    Table EMEA Hemoglobinopathies Drugs Sale Price (USD/Pcs) by Type (2012-2017)
    Table EMEA Hemoglobinopathies Drugs Sales (K Pcs) and Market Share by Application (2012-2017)
    Table EMEA Hemoglobinopathies Drugs Sales Share by Application (2012-2017)
    Figure Sales Market Share of Hemoglobinopathies Drugs by Application (2012-2017)
    Figure EMEA Hemoglobinopathies Drugs Sales Market Share by Application in 2016
    Table EMEA Hemoglobinopathies Drugs Sales (K Pcs) and Market Share by Region (2012-2017)
    Table EMEA Hemoglobinopathies Drugs Sales Share by Region (2012-2017)
    Figure Sales Market Share of Hemoglobinopathies Drugs by Region (2012-2017)
    Figure EMEA Hemoglobinopathies Drugs Sales Market Share in 2016
    Table EMEA Hemoglobinopathies Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
    Table EMEA Hemoglobinopathies Drugs Revenue Share by Region (2012-2017)
    Figure Revenue Market Share of Hemoglobinopathies Drugs by Region (2012-2017)
    Figure EMEA Hemoglobinopathies Drugs Revenue Market Share Regions in 2016
    Table EMEA Hemoglobinopathies Drugs Sales Price (USD/Pcs) by Region (2012-2017)
    Figure Europe Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Europe Hemoglobinopathies Drugs Revenue and Growth Rate (2012-2017)
    Table Europe Hemoglobinopathies Drugs Sales (K Pcs) by Type (2012-2017)
    Table Europe Hemoglobinopathies Drugs Market Share by Type (2012-2017)
    Figure Europe Hemoglobinopathies Drugs Market Share by Type in 2016
    Table Europe Hemoglobinopathies Drugs Sales (K Pcs) by Application (2012-2017)
    Table Europe Hemoglobinopathies Drugs Market Share by Application (2012-2017)
    Figure Europe Hemoglobinopathies Drugs Market Share by Application in 2016
    Table Europe Hemoglobinopathies Drugs Sales (K Pcs) by Countries (2012-2017)
    Table Europe Hemoglobinopathies Drugs Sales Market Share by Countries (2012-2017)
    Figure Europe Hemoglobinopathies Drugs Sales Market Share by Countries (2012-2017)
    Figure Europe Hemoglobinopathies Drugs Sales Market Share by Countries in 2016
    Table Europe Hemoglobinopathies Drugs Revenue (Million USD) by Countries (2012-2017)
    Table Europe Hemoglobinopathies Drugs Revenue Market Share by Countries (2012-2017)
    Figure Europe Hemoglobinopathies Drugs Revenue Market Share by Countries (2012-2017)
    Figure Europe Hemoglobinopathies Drugs Revenue Market Share by Countries in 2016
    Figure Germany Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure France Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure UK Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Russia Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Italy Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Benelux Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Middle East Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Middle East Hemoglobinopathies Drugs Revenue (Million USD) and Growth Rate (2012-2017)
    Table Middle East Hemoglobinopathies Drugs Sales (K Pcs) by Type (2012-2017)
    Table Middle East Hemoglobinopathies Drugs Market Share by Type (2012-2017)
    Figure Middle East Hemoglobinopathies Drugs Market Share by Type (2012-2017)
    Table Middle East Hemoglobinopathies Drugs Sales (K Pcs) by Applications (2012-2017)
    Table Middle East Hemoglobinopathies Drugs Market Share by Applications (2012-2017)
    Figure Middle East Hemoglobinopathies Drugs Sales Market Share by Application in 2016
    Table Middle East Hemoglobinopathies Drugs Sales Volume (K Pcs) by Countries (2012-2017)
    Table Middle East Hemoglobinopathies Drugs Sales Volume Market Share by Countries (2012-2017)
    Figure Middle East Hemoglobinopathies Drugs Sales Volume Market Share by Countries in 2016
    Table Middle East Hemoglobinopathies Drugs Revenue (Million USD) by Countries (2012-2017)
    Table Middle East Hemoglobinopathies Drugs Revenue Market Share by Countries (2012-2017)
    Figure Middle East Hemoglobinopathies Drugs Revenue Market Share by Countries (2012-2017)
    Figure Middle East Hemoglobinopathies Drugs Revenue Market Share by Countries in 2016
    Figure Saudi Arabia Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Israel Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure UAE Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Iran Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Africa Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Africa Hemoglobinopathies Drugs Revenue (Million USD) and Growth Rate (2012-2017)
    Table Africa Hemoglobinopathies Drugs Sales (K Pcs) by Type (2012-2017)
    Table Africa Hemoglobinopathies Drugs Sales Market Share by Type (2012-2017)
    Figure Africa Hemoglobinopathies Drugs Sales Market Share by Type (2012-2017)
    Figure Africa Hemoglobinopathies Drugs Sales Market Share by Type in 2016
    Table Africa Hemoglobinopathies Drugs Sales (K Pcs) by Application (2012-2017)
    Table Africa Hemoglobinopathies Drugs Sales Market Share by Application (2012-2017)
    Figure Africa Hemoglobinopathies Drugs Sales Market Share by Application (2012-2017)
    Table Africa Hemoglobinopathies Drugs Sales Volume (K Pcs) by Countries (2012-2017)
    Table Africa Hemoglobinopathies Drugs Sales Market Share by Countries (2012-2017)
    Figure Africa Hemoglobinopathies Drugs Sales Market Share by Countries (2012-2017)
    Figure Africa Hemoglobinopathies Drugs Sales Market Share by Countries in 2016
    Table Africa Hemoglobinopathies Drugs Revenue (Million USD) by Countries (2012-2017)
    Table Africa Hemoglobinopathies Drugs Revenue Market Share by Countries (2012-2017)
    Figure Africa Hemoglobinopathies Drugs Revenue Market Share by Countries (2012-2017)
    Figure Africa Hemoglobinopathies Drugs Revenue Market Share by Countries in 2016
    Figure South Africa Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Nigeria Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Egypt Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Algeria Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Table Gamida Cell Hemoglobinopathies Drugs Basic Information List
    Table Gamida Cell Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
    Figure Gamida Cell Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Gamida Cell Hemoglobinopathies Drugs Sales Market Share in EMEA (2012-2017)
    Figure Gamida Cell Hemoglobinopathies Drugs Revenue Market Share in EMEA (2012-2017)
    Table Alnylam Pharmaceuticals Hemoglobinopathies Drugs Basic Information List
    Table Alnylam Pharmaceuticals Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
    Figure Alnylam Pharmaceuticals Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Alnylam Pharmaceuticals Hemoglobinopathies Drugs Sales Market Share in EMEA (2012-2017)
    Figure Alnylam Pharmaceuticals Hemoglobinopathies Drugs Revenue Market Share in EMEA (2012-2017)
    Table Biogen Idec Hemoglobinopathies Drugs Basic Information List
    Table Biogen Idec Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
    Figure Biogen Idec Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Biogen Idec Hemoglobinopathies Drugs Sales Market Share in EMEA (2012-2017)
    Figure Biogen Idec Hemoglobinopathies Drugs Revenue Market Share in EMEA (2012-2017)
    Table Sangamo BioSciences Inc. Hemoglobinopathies Drugs Basic Information List
    Table Sangamo BioSciences Inc. Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
    Figure Sangamo BioSciences Inc. Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Sangamo BioSciences Inc. Hemoglobinopathies Drugs Sales Market Share in EMEA (2012-2017)
    Figure Sangamo BioSciences Inc. Hemoglobinopathies Drugs Revenue Market Share in EMEA (2012-2017)
    Table Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Basic Information List
    Table Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
    Figure Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Sales Market Share in EMEA (2012-2017)
    Figure Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Revenue Market Share in EMEA (2012-2017)
    Table Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Basic Information List
    Table Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
    Figure Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Sales Market Share in EMEA (2012-2017)
    Figure Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Revenue Market Share in EMEA (2012-2017)
    Table Pfizer Inc. Hemoglobinopathies Drugs Basic Information List
    Table Pfizer Inc. Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
    Figure Pfizer Inc. Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Pfizer Inc. Hemoglobinopathies Drugs Sales Market Share in EMEA (2012-2017)
    Figure Pfizer Inc. Hemoglobinopathies Drugs Revenue Market Share in EMEA (2012-2017)
    Table Mast Therapeutics Hemoglobinopathies Drugs Basic Information List
    Table Mast Therapeutics Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
    Figure Mast Therapeutics Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Mast Therapeutics Hemoglobinopathies Drugs Sales Market Share in EMEA (2012-2017)
    Figure Mast Therapeutics Hemoglobinopathies Drugs Revenue Market Share in EMEA (2012-2017)
    Table Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Basic Information List
    Table Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
    Figure Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Sales Market Share in EMEA (2012-2017)
    Figure Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Revenue Market Share in EMEA (2012-2017)
    Table Prolong Pharmaceuticals Hemoglobinopathies Drugs Basic Information List
    Table Prolong Pharmaceuticals Hemoglobinopathies Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
    Figure Prolong Pharmaceuticals Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate (2012-2017)
    Figure Prolong Pharmaceuticals Hemoglobinopathies Drugs Sales Market Share in EMEA (2012-2017)
    Figure Prolong Pharmaceuticals Hemoglobinopathies Drugs Revenue Market Share in EMEA (2012-2017)
    Table Celgene Corporation Hemoglobinopathies Drugs Basic Information List
    Table HemaQuest Pharmaceuticals Hemoglobinopathies Drugs Basic Information List
    Table Production Base and Market Concentration Rate of Raw Material
    Figure Price Trend of Key Raw Materials
    Table Key Suppliers of Raw Materials
    Figure Manufacturing Cost Structure of Hemoglobinopathies Drugs
    Figure Manufacturing Process Analysis of Hemoglobinopathies Drugs
    Figure Hemoglobinopathies Drugs Industrial Chain Analysis
    Table Raw Materials Sources of Hemoglobinopathies Drugs Major Manufacturers in 2016
    Table Major Buyers of Hemoglobinopathies Drugs
    Table Distributors/Traders List
    Figure EMEA Hemoglobinopathies Drugs Sales (K Pcs) and Growth Rate Forecast (2017-2022)
    Figure EMEA Hemoglobinopathies Drugs Revenue and Growth Rate Forecast (2017-2022)
    Figure EMEA Hemoglobinopathies Drugs Price (USD/Pcs) and Trend Forecast (2017-2022)
    Table EMEA Hemoglobinopathies Drugs Sales (K Pcs) Forecast by Region (2017-2022)
    Figure EMEA Hemoglobinopathies Drugs Sales Market Share Forecast by Region (2017-2022)
    Table EMEA Hemoglobinopathies Drugs Revenue (Million USD) Forecast by Region (2017-2022)
    Figure EMEA Hemoglobinopathies Drugs Revenue Market Share Forecast by Region (2017-2022)
    Table Europe Hemoglobinopathies Drugs Sales (K Pcs) Forecast by Countries (2017-2022)
    Figure Europe Hemoglobinopathies Drugs Sales Market Share Forecast by Countries (2017-2022)
    Table Europe Hemoglobinopathies Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
    Figure Europe Hemoglobinopathies Drugs Revenue Market Share Forecast by Countries (2017-2022)
    Table Middle East Hemoglobinopathies Drugs Sales (K Pcs) Forecast by Countries (2017-2022)
    Figure Middle East Hemoglobinopathies Drugs Sales Market Share Forecast by Countries (2017-2022)
    Table Middle East Hemoglobinopathies Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
    Figure Middle East Hemoglobinopathies Drugs Revenue Market Share Forecast by Countries (2017-2022)
    Table Africa Hemoglobinopathies Drugs Sales (K Pcs) Forecast by Countries (2017-2022)
    Figure Africa Hemoglobinopathies Drugs Sales Market Share Forecast by Countries (2017-2022)
    Table Africa Hemoglobinopathies Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
    Figure Africa Hemoglobinopathies Drugs Revenue Market Share Forecast by Countries (2017-2022)
    Table EMEA Hemoglobinopathies Drugs Sales (K Pcs) Forecast by Type (2017-2022)
    Figure EMEA Hemoglobinopathies Drugs Sales Market Share Forecast by Type (2017-2022)
    Table EMEA Hemoglobinopathies Drugs Sales (K Pcs) Forecast by Application (2017-2022)
    Figure EMEA Hemoglobinopathies Drugs Sales Market Share Forecast by Application (2017-2022)
    Table Research Programs/Design for This Report
    Figure Bottom-up and Top-down Approaches for This Report
    Figure Data Triangulation
    Table Key Data Information from Secondary Sources
    Table Key Data Information from Primary Sources